INITIATOR PHARMA: INTERIM REPORT JANUARY- MARCH 2021
Business highlights in Q1 2021 · On January 14[th] the EGM approved the proposed convertible financing agreement with MAC Clinical Research, covering up to SEK 23 million (approx. DKK 17 million) of the clinical trial costs for the planned Phase 2b trial with IPED2015 in Erectile Dysfunction. Significant events after this reporting period · On April 13[th] it was announced a proposal for a directed issue and fully guaranteed preferential rights issue of total SEK 60 million to expand into new orphan drug indication, led by long-term investors Linc AB and Adrigo Asset